Quest Diagnostics Q2 2024 Earnings Preview
Notable Earnings Before Tuesday's Open
Quest Diagnostics Market Position and Earnings Potential: Analyst Pito Chickering's Outlook Amidst Inflationary Challenges and Growth Strategies
Tesla, AT&T, Alphabet, Chipotle, Visa, and More Stocks to Watch This Week
Second-quarter earnings season continues with Verizon, Alphabet, Coca-Cola, Comcast, General Motors, Tesla, Visa, AT&T, Chipotle, and Newmont.
Labcorp, Quest Among Health Firms to Cite Impact From CrowdStrike Issue
Express News | Quest Diagnostics - Patient Services & Customer Contact Teams Operating With Reduced Capacity, so Customers May Experience Longer Wait & Service Times
Express News | Quest Diagnostics Says Taking Swift Action to Respond, Recover and Restore Operations Due to Global Information Outage That Occurred This Morning
Boeing admitted to guilt for violating the agreement related to the 737Max crash incident.
Boeing will admit to criminal conspiracy charges related to the two fatal crashes of its 737 Max aircraft, a deal that shames the famed American aircraft maker but avoids a courtroom showdown as it tries to recover from multiple crises. Under an agreement reached with U.S. prosecutors, Boeing faces a criminal fine of as much as $487.2 billion - the highest amount allowed by law - but the actual amount will be decided by a judge, the Justice Department said. The Justice Department is seeking the judge to credit the prior fines paid by Boeing, which would bring the new penalty down to 2 billion US dollars if approved.
Lisata to Use Haystack Technology to Evaluate Pancreatic Cancer Asset Certepetide
Express News | Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack Mrd™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
Express News | EXCLUSIVE: Lisata Therapeutics Tells Benzinga Co. And Haystack Oncology Initiate Research Collaboration To Use The Haystack MRD Technology To Evaluate Efficacy Of Pancreatic Cancer Therapy
Here's Why Quest Diagnostics (DGX) Is a Strong Value Stock
Quest Diagnostics Is Maintained at Hold by Truist Securities
Quest Diagnostics Is Maintained at Hold by Truist
Quest Diagnostics Price Target Raised to $158.00/Share From $150.00 by Truist Securities
Quest Diagnostics Price Target Raised to $158.00/Share From $150.00 by Truist
Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $158
Truist Financial analyst David S Macdonald maintains $Quest Diagnostics(DGX.US)$ with a hold rating, and adjusts the target price from $145 to $158.According to TipRanks data, the analyst has a
Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services
Truist Securities Adjusts Price Target on Quest Diagnostics to $158 From $150, Maintains Hold Rating
Quest Diagnostics (DGX) has an average outperform rating and a price target range of $136 to $165, according to analysts polled by Capital IQ.
Is Quest Diagnostics Incorporated (DGX) an Undervalued High Growth Stock?
Express News | Quest Diagnostics Inc : Leerink Partners Raises Target Price to $151 From $141
What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?